Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

The company is on the lookout for partners to advance vaccine contenders. Novavax Inc. is starting to look like a vaccine development company again. The Gaithersburg biotech is two years into its ...

The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate. Also Read: Wegovy Maker Novo Nordisk To Buy Novavax ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland ...

Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from ...